Table 1 Evaluation of pharmacokinetic interactions between TKIs and docetaxel in patients
From: Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations
TKI | Docetaxel dose (mg m−2) | Observation | Reference |
|---|---|---|---|
Axitinib | 100 | AUC ∼55% increased | |
Bosutinib | NA | ||
Crizotinib | NA | ||
Dasatinib | 75 | No change | |
Erlotinib | 25 | No change | |
Gefitinib | 75 | No change | |
Imatinib | 20–25 | No change | |
Lapatinib | 75 | No change | |
Nilotinib | NA | ||
Pazopanib | 50–60 | AUC ∼57% increased | |
Regorafenib | NA | ||
Ruxolitinib | NA | ||
Sorafenib | 75–100 | AUC ∼36–80% increased | |
Sunitinib | 75 | No change | |
Vandetanib | NA | ||
Vemurafenib | NA |
